Use este identificador para citar ou linkar para este item: http://repositorio.ufla.br/jspui/handle/1/50852
Registro completo de metadados
Campo DCValorIdioma
dc.creatorCastro, Alexandre A. de-
dc.creatorAssis, Letícia C.-
dc.creatorCunha, Elaine F. F. da-
dc.creatorRamalho, Teodorico C.-
dc.creatorLa Porta, Felipe A.-
dc.date.accessioned2022-08-05T18:31:37Z-
dc.date.available2022-08-05T18:31:37Z-
dc.date.issued2022-
dc.identifier.citationCASTRO, A. A. de et al. New In Silico insights into the application of (Hydroxy)Chloroquine with Macrolide Antibiotic Co-Crystals against the SARS-CoV-2 Virus. Covid, [S. l.], v. 2, n. 3, p. 230-243, 2022. DOI: 10.3390/covid2030018.pt_BR
dc.identifier.urihttp://repositorio.ufla.br/jspui/handle/1/50852-
dc.description.abstractIn this in silico study, different pharmaceutical co-crystals based on (hydroxy)chloroquine with macrolide antibiotics (azithromycin, clarithromycin, or erythromycin A) were analyzed for the first time. These findings present a new molecular perspective and therefore suggest that the combination of (hydroxy)chloroquine/azithromycin, in the stoichiometric ratio of 1:1, as model co-crystal systems has less toxicity and is the most effective for inhibiting the new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).pt_BR
dc.languageen_USpt_BR
dc.publisherMDPIpt_BR
dc.rightsAttribution 4.0 International*
dc.rightsacesso abertopt_BR
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.sourceCovidpt_BR
dc.subject(hydroxy)chloroquinept_BR
dc.subjectMacrolide antibioticspt_BR
dc.subjectCo-crystalspt_BR
dc.subjectSARS-CoV-2pt_BR
dc.subjectMolecular modellingpt_BR
dc.subjectHidroxicloroquinapt_BR
dc.subjectAntibióticos macrolídeospt_BR
dc.subjectCocristaispt_BR
dc.subjectModelagem molecularpt_BR
dc.titleNew In Silico insights into the application of (Hydroxy)Chloroquine with Macrolide Antibiotic Co-Crystals against the SARS-CoV-2 Viruspt_BR
dc.typeArtigopt_BR
Aparece nas coleções:DQI - Artigos publicados em periódicos



Este item está licenciada sob uma Licença Creative Commons Creative Commons